Combination of novel HER2-targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2-positive gastric cancer

Molecular Oncology

Volumn 9, Issue 2, 2015, Pages 398-408

  Ko, Bong Kook ^a,d   Lee, Sook Yeon ^a   Lee, Young Ha ^a   Hwang, In Sik ^a   Persson, Helena ^b   Rockberg, Johan ^c   Borrebaeck, Carl ^b   Park, Dongeun ^d   Kim, Kyu Tae ^a   Uhlen, Mathias ^c   Lee, Jong Seo ^a  

^a Ace Twin Tower 1   (South Korea)

^b LUND UNIVERSITY   (Sweden)

^c ROYAL INSTITUTE OF TECHNOLOGY   (Sweden)

^d Seoul National University   (South Korea)

Author keywords

1E11; Combination; Gastric cancer; HER2; Synergism; Trastuzumab

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 1E11; PERTUZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; CANCER ANTIBODY; ERBB2 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; GASTRIC CANCER CELL LINE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; STOMACH CANCER; ANTAGONISTS AND INHIBITORS; METABOLISM; PATHOLOGY; STOMACH NEOPLASMS; TUMOR CELL LINE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SYNERGISM; HUMANS; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84921371099     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2014.09.007     Document Type: Article

References (49)

1. Arnould L.1, Gelly M., Penault-Llorca F., Benoit L., Bonnetain F., Migeon C., Cabaret V., Fermeaux V., Bertheau P., Garnier J., Jeannin J.F., Coudert B. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism. Br. J. Cancer 2006, 94:259-267.
2. Balana M.E., Labriola L., Salatino M., Movsichoff F., Peters C., Charreau E.H., Elizalde P.V. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene 2001, 20:34-47.
3. Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprille G., Kulikov E., Hill J., Lehle M., Ruschoff J., Kang Y.K. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3, open-label, randomized controlled trial. Lancet 2010, 376:687-697. ToGA Trial Investigators.
4. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat. Rev. Cancer 2009, 9:463-475.
5. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., Bianchi G., Cortes J., McNally V.A., Ross G.A., Fumoleau P., Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J.Clin. Oncol. 2010, 28:1138-1144.
6. Baselga J., Cortes J., Kim S.B., Im S.A., Hegg R., Im Y.H., Roman L., Pedrini J.L., Pienkowski T., Knott A., Clark E., Benyunes M.C., Ross G., Swain S.M. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Eng. J. Med. 2012, 366:109-119. CLEOPATRA Study Group.
7. Ben-Kasus T., Schechter B., Sela M., Yarden Y. Cancer therapeutic antibodies come of age: targeting minimal residual disease. Mol. Oncol. 2007, 1:42-54.
8. Ben-Kasus T., Schechter B., Lavi S., Yarden Y., Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc. Natl. Acad. Sci. U S A 2009, 106:3294-3299.
9. Bourguignon L.Y., Zhu H., Chu A., Iida N., Zhang L., Hung M.C. Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J.Biol. Chem. 1997, 272:27913-27918.
10. Brochet X., Lefrance M.P., Giudicelli V. IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis. Nucleic Acids Res. 2008, 36:W503-W508.
11. Brockhoff G., Heckel B., Schmidt-Bruecken E., Plander M., Hofstaedter F., Vollmann A., Diermeier S. Differential impact of Cetuximab, Pertuzumab and Trastuzumab on BT474 and SK-BR-3 breast cancer cell proliferation. Cell Prolif. 2007, 40:488-507.
12. Burgess A.W., Cho H.S., Eigenbrot C., Ferguson K.M., Garrett T.P., Leahy D.J., Lemmon M.A., Sliwkowski M.X., Ward C.W., Yokoyama S. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 2003, 12:541-552.
13. Cai Z., Zhang G., Zhou Z., Bembas K., Drebin J.A., Greene M.I., Zhang H. Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes. Oncogene 2008, 27:3870-3874.
14. Chakrabarty A., Bhola N.E., Sutton C., Ghosh R., Kuba M.G., Dave B., Chang J.C., Arteaga C.L. Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013, 73:1190-1200.
15. Cho H.S., Mason K., Ramyar K.X., Stanley A.M., Gabelli S.B., Denney D.W., Leahy D.J. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003, 421:756-760.
16. Chou T.C., Talalay P. Quantitative analysis of dose-effect relationships: the combination effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 1984, 22:27-55.
17. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., Greenberg M.E. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
18. Ding Y., Liu Z., Desai S., Zhao Y., Liu H., Pannell L.K., Yi H., Wright E.R., Owen L.B., Dean-Colomb W., Fodstad O., Lu J., LeDoux S.P., Wilson G.L., Tan M. Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism. Nat. Commun. 2012, 3:1271.
19. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet] 2013, International Agency for Research on Cancer, Lyon, France, Available from:, (accessed on day/month/year). http://globocan.iarc.fr.
20. Foote J., Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J.Mol. Biol. 1992, 224:487-499.
21. Friedman L.M., Rinon A., Schechter B., Lyass L., Lavi S., Bacus S.S., Sela M., Yarden Y. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc. Natl. Acad. Sci. U S A 2005, 102:1915-1920.
22. Garcia I., Vizoso F., Martin A., Sanz L., Abdel-Lah O., Raigoso P., Garcia-Muniz J.L. Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann. Surg. Oncol. 2003, 10:234-241.
23. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
24. Hayashi M., Inokuchi M., Takagi Y., Yamada H., Kojima K., Kumagai J., Kawano T., Sugihara K. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin. Cancer Res. 2008, 14:7843-7849.
25. Hofmeister J.K., Cooney D., Coggeshall K.M. Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. Blood Cells Mol. Dis. 2000, 26:133-143.
26. Huang S.M., Bock J.M., Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59:1935-1940.
27. Junttila T.T., Akita R.W., Parsons K., Fields C., Lewis Phillips G.D., Friedman L.S., Sampath D., Sliwkowski M.X. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell 2009, 15:429-440.
28. Kamat V., Donaldson J.M., Kari C., Quadros M.R., Lelkes P.I., Chaiken I., Cocklin S., Williams J.C., Papazoglou E., Rodeck U. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol. Ther. 2008, 7:726-733.
29. Kasprzyk P.G., Song S.U., Di Fiore P.P., King C.R. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Res. 1992, 52:2771-2776.
30. Kim S.Y., Kim H.P., Kim Y.J., Oh do Y., Im S.A., Lee D., Jong H.S., Kim T.Y., Bang Y.J. Trastuzumab inhibits the growth of human gastric cancer cell lines with HER2 amplification synergistically with cisplatin. Int. J. Oncol. 2008, 32:89-95.
31. Koefoed K., Steinaa L., Soderberg J.N., Kjar I., Jacobsen H.J., Meijer P.J., Haurum J.S., Jensen A., Kragh M., Andersen P.S., Pedersen M.W. Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor. MAbs 2011, 3:584-595.
32. Lee-Hoeflich S.T., Crocker L., Yao E., Pham T., Munroe X., Hoeflich K.P., Sliwkowski M.X., Stern H.M. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 2008, 68:5878-5887.
33. Nagy P., Friedlander E., Tanner M., Kapanen A.I., Carraway K.L., Isola J., Jovin T.M. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a Herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 2005, 65:473-482.
34. Nahta R., Hung M.C., Esteva F.J. The HER2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004, 64:2343-2346.
35. Nahta R., Yuan L.X., Zhang B., Kobayashi R., Esteva F.J. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer. Cancer Res. 2005, 65:11118-11128.
36. Olayioye M.A., Neve R.M., Lane H.A., Hynes N.E. The ErbB signaling network: receptor dimerization in development and cancer. EMBO J. 2000, 19:3159-3167.
37. Patel D., Bassi R., Hooper A., Prewett M., Hicklin D.J., Kang X. Anti-epidermal growth factor receptor monoclonal antibody cetuximab inhibits EGFR/HER-2 heterodimerization and activation. Int. J. Oncol. 2009, 34:25-32.
38. Pedersen M.W., Jacobsen H.J., Koefoed K., Hey A., Pyke C., Haurum J.S., Kragh M. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res. 2010, 70:588-597.
39. Real P.J., Benito A., Cuevas J., Berciano M.T., de Juan A., Coffer P., Gomez-Roman J., Lafarga M., Lopez-Vega J.M., Fernandez-Luna J.L. Blockade of epidermal growth factor receptors chemosensitizes breast cancer cells through up-regulation of Bnip3L. Cancer Res. 2005, 65:8151-8157.
40. Sakai K., Yokote H., Murakami-Murofushi K., Tamura T., Saijo N., Nishio K. Pertuzumab, a novel HER2 dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci. 2007, 98:1498-1503.
41. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strong enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69:9330-9336.
42. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J. Clin. 2012, 62:10-29.
43. Susnow N., Zeng L., Margineantu D., Hockenbery D.M. Bcl-2 family proteins as regulators of oxidative stress. Semin. Cancer Biol. 2009, 19:42-49.
44. Tanizaki J., Okamoto I., Fumita S., Okamoto W., Nishio K., Nakagawa K. Roles of BIM induction and surviving downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification. Oncogene 2011, 30:4097-4106.
45. Tanner M., Hollmen M., Junttila T.T., Kapanen A.I., Tommola S., Soini Y., Helin H., Salo J., Joensuu H., Sihvo E., Elenius K., Isola J. Amplification of HER-2 in gastric cancer: association with topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann. Oncol. 2005, 16:273-278.
46. Tvorogov D., Anisimov A., Zheng W., Leppanen V.M., Tammela T., Laurinavicius S., Holnthoner W., Helotera H., Holopainen T., Jeltsch M., Kalkkinen N., Lankinen H., Ojala P.M., Alitalo K. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 2010, 18:630-640.
47. Yamashita-Kashima Y., Iijima S., Yorozu K., Furugaki K., Kurasawa M., Ohta M., Fujimoto-Ouchi K. Pertuzumab in combination with trastuzumab shows significant enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin. Cancer Res. 2011, 17:5060-5070.
48. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nat. Rev. Mol. Cell Biol. 2001, 2:127-137.
49. Zhang A., Shen G., Zhao T., Zhang G., Liu J., Song L., Wei W., Bing L., Wu Z., Wu Q. Augmented inhibition of angiogenesis by combination of HER2 antibody chA21 and trastuzumab in human ovarian carcinoma xenograft. J.Ovarian Res. 2010, 3:20.